Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GoodRx Holdings, Inc.GDRX · Entity 4838 | See Remarks | June 08, 2023 | June 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GoodRx Holdings, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 44,005 |
Ending reported balance
After 2023-06-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-08 · Exercise / conversion · Acquired 20,401 · Balance 51,060 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Row 2 · 2023-06-08 · Tax withholding · Disposed 7,055 · Balance 44,005 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 265,220 |
Reported balance
After 2023-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-08 · Exercise / conversion · Disposed 20,401 · Balance 265,220 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2: The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximtely equal quarterly installments thereafter for 15 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
F2: The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximtely equal quarterly installments thereafter for 15 quarters.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2021 Filed Jun 2, 2021 18:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 70,833 | $5.94 | $420,748.02 |
DisclosureSEC source: 0000899243-21-021638 · doc4.xml · nonDerivative · entry 1 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:20 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0000899243-21-019305 · doc4.xml · derivative · entry 5 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,917 Underlying: Class A Common Stock · 12,500 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:20 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 5,256 | $33.53 | $176,221.07 |
DisclosureSEC source: 0000899243-21-019305 · doc4.xml · nonDerivative · entry 4 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $34.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:20 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 4,519 | $33.17 | $149,896.13 |
DisclosureSEC source: 0000899243-21-019305 · doc4.xml · nonDerivative · entry 3 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,256 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.39 to $33.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:20 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 2,725 | $31.80 | $86,664.27 |
DisclosureSEC source: 0000899243-21-019305 · doc4.xml · nonDerivative · entry 2 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,775 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.34. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:20 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 12,500 | $5.94 | $74,250.00 |
DisclosureSEC source: 0000899243-21-019305 · doc4.xml · nonDerivative · entry 1 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:03 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,833 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0000899243-21-018376 · doc4.xml · derivative · entry 4 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,417 Underlying: Class A Common Stock · 70,833 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:03 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 4,350 | $39.79 | $173,090.85 |
DisclosureSEC source: 0000899243-21-018376 · doc4.xml · nonDerivative · entry 3 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.67 to $40.02. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:03 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 66,483 | $39.08 | $2,597,962.84 |
DisclosureSEC source: 0000899243-21-018376 · doc4.xml · nonDerivative · entry 2 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,350 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.67 to $39.66. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:03 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 70,833 | $5.94 | $420,748.02 |
DisclosureSEC source: 0000899243-21-018376 · doc4.xml · nonDerivative · entry 1 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:53 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0000899243-21-015573 · doc4.xml · derivative · entry 4 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,250 Underlying: Class A Common Stock · 12,500 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:53 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 888 | $40.16 | $35,662.08 |
DisclosureSEC source: 0000899243-21-015573 · doc4.xml · nonDerivative · entry 3 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This price reported in Column 4 is a werighted average price. These shares were sold in multiple transactions at prices ranging from $40.14 to $40.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:53 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 11,612 | $39.66 | $460,540.05 |
DisclosureSEC source: 0000899243-21-015573 · doc4.xml · nonDerivative · entry 2 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $40.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:53 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 12,500 | $5.94 | $74,250.00 |
DisclosureSEC source: 0000899243-21-015573 · doc4.xml · nonDerivative · entry 1 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:22 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,250 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0000899243-21-014868 · doc4.xml · derivative · entry 4 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,750 Underlying: Class A Common Stock · 21,250 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:22 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 11,078 | $40.06 | $443,774.71 |
DisclosureSEC source: 0000899243-21-014868 · doc4.xml · nonDerivative · entry 3 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This price reported in Column 4 is a werighted average price. These shares were sold in multiple transactions at prices ranging from $39.84 to $40.52. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:22 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 10,172 | $39.24 | $399,162.50 |
DisclosureSEC source: 0000899243-21-014868 · doc4.xml · nonDerivative · entry 2 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,078 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 to $39.78. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:22 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 21,250 | $5.94 | $126,225.00 |
DisclosureSEC source: 0000899243-21-014868 · doc4.xml · nonDerivative · entry 1 Azad Babak · CIK 0001822193 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.